Theta burst stimulation for suicidal ideation in depression: A systematic review and meta-analysis of efficacy and protocol moderators.

Psychiatry ResMay 16, 2026 (epub)
Clinical ResearchPsychiatry

Xin Xia, Xinyi Feng, Chuan Huang et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy of theta burst stimulation (TBS) on suicidal ideation (SI) and depressive symptoms in patients with major depressive disorder. Eighteen studies were included, with 14 contributing to quantitative analysis. TBS significantly reduced SI (SMD = -0.48, p < 0.001) and depressive symptoms (SMD = -0.66, p < 0.001), indicating its potential as a rapid intervention.

Key findings

  • TBS significantly reduced suicidal ideation with a standardized mean difference of -0.48.
  • TBS also significantly decreased depressive symptoms with a standardized mean difference of -0.66.
  • Baseline depression severity moderated the anti-suicidal effects of TBS (β = -2.777, p = 0.007).
  • No serious adverse events were reported during the studies.

Why it matters

The findings suggest that TBS could provide a rapid and effective treatment option for patients experiencing suicidal ideation in the context of major depressive disorder, addressing a critical need for timely interventions.

Source

PubMed · PMID 42155351

Published in Psychiatry Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.